Immupharma Share Discussion Threads

[aussieb3] 22/12/2017 14:35

Cheers pal been busy as last few days lol forgot it finished early today

[che7win] 22/12/2017 14:34

market closed at 12:30 aussie

If bored, you could watch Bitcoins crashing very quickly.

[aussieb3] 22/12/2017 14:27

Weird price and not changed in last 2 hours or any trades is there a fault with advfn

[professor bang bang] 22/12/2017 12:47

Improvement rates with Lupuzor

Phase 2b at 3 months = + 67.6%
Phase 2b at 6 months = + 84.2%
Phase 3 at 9 - 12 months = + 100% ??

For me its not now about whether lupuzor works but just how big the improvement will be at 9 and 12 months.

N.B.
Resetting the Autoreactive Immune System with a Therapeutic Peptide in Lupus
Prof. Sylvian Muller
Lupus (2015) 24, pg 412–418

"The phase IIb trial showed that after three months of therapy (three subcutaneous injections of 200 ug peptide/patient in addition to standard of care), Lupuzor improved Systemic Lupus Erythematosus Disease Activity Index score of lupus patients under active treatment by 67.6% versus 41.5% in the placebo group (p<0.025). After three additional months of follow-up, the improvement rate was 84.2% versus 45.8% (p<0.025). The side effect profile was unproblematic and the drug was well tolerated as evidenced by a very low drop-out rate."

www.lupuzor.com/Documents/Schall%20Muller%20Lupus%202015.pdf

[sportbilly1976] 22/12/2017 12:42

back above 160 :)

Have a fab Christmas all...back next week & then hopefully 2018 can be THE year for IMM & it's shareholders (and also lest we forget the patients who will massively benefit from the treatment being tested currently)

[spawny100] 22/12/2017 12:29

Nice little spike to end on

[hamhamham1] 22/12/2017 12:27

Ooh. Maybe a sign of thing to come ;)

[hamhamham1] 22/12/2017 12:17

TopTips and MoneyMaker. As it's Christmas am gonna let your exuberance get to me today and but dream :)
"This time next year Rodders...."

[top tips] 22/12/2017 10:57

Money maker looks spot on. Precedents include GSK's takeover of HGSi to get their lupus drug Benlysta and Gilead's recent takeover of Kite Pharma, etc.

[obiterdicta] 22/12/2017 10:42

MM1 If each £10.00 of share price equates to £1.3 billion, £40.00 share price equates to £5.2 billion. Are pharma acquisitions at 5.2 x sales? If so, you are bang on.

OD

[hamhamham1] 22/12/2017 10:27

What are the odds for a 153p (on the nose) close today?

[money maker1] 22/12/2017 09:06

The shares are probably worth around £40 for each $billion of sales, so multi-billion sales means at least £80 for starters.

[hamhamham1] 22/12/2017 08:54

L0ngterm. And if these generous gifts are to reward staff or others. Then it's not much of a reward for their hard work if the option is at 153p and if the share price is forecast to be around that level or below?
So you would assume IMM are confident it's going to be a lot higher?

[englishlongbow] 22/12/2017 08:33

So even Shares Magazine is saying Lupuzor could get multi billion $ annual sales.

[l0ngterm] 21/12/2017 21:45

Markets essentially shut..

[davew28] 21/12/2017 21:30

Lt
Not how the market has interpreted it so far anyway

[lukead] 21/12/2017 21:16

A nice mention in shares mag, thanks for sharing and should be a few more tips in the next couple of weeks. IMM due 1st quarter and if successful the main drug is multi billion whilst MTFB not for late 2018

[l0ngterm] 21/12/2017 20:51

If you take the stance that the options are generous gifts to staff etc. Then it has already been leaked.

[top tips] 21/12/2017 20:51

Shares Magazine
Small caps poised for big news in 2018:
We look at 19 stocks primed to deliver major events in their career
21/12/2017



"Drug developer ImmuPharma (IMM) is expecting Phase III results in the first quarter of 2018 for lupus treatment Lupuzor. Analysts speculate the drug could hit multi-billion dollar annual sales if the tests are successful and the drug gets approved by the regulators."

[davew28] 21/12/2017 20:48

If the last patient has been dosed with an estimated completion of 17th of January, surely the results will then be unblinded and since Simbec-Orion have been collating on-going progress can be reported. I can't understand why some are talking of February/March for reporting? If that's the case with a gap between unblinding and reporting via RNS, there's bound to be leakage.

[someuwin] 21/12/2017 20:20

Small Caps Poised for big news in 2018...

[hottingup] 21/12/2017 18:39

The announcement referred to, "consultants who have been directly involved in Lupuzor(TM)'s successful development to date", so presumably it could be CNRS or persons within that team, which could include Sylviane Muller and her close colleagues, e.g. Helene Jeltsch-David, Hayet Dali and Nicolas Schall. Interestingly, Sylviane listed them by name in a presentation last year, so she obviously feels they have played an important part in developing Lupuzor.

Last slide, 46 min 47 sec: